Effects of Pentazocine Versus Lorazepam on Manic Symptoms

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mclean Hospital
• Collaborator: Stanley Medical Research Institute
• Treatments: Lorazepam; Pentazocine

Criteria

Inclusion Criteria:

• bipolar or schizoaffective disorder

• currently manic

• no acute medical issues

• no substance withdrawal

Exclusion Criteria:

• unable to give informed consent

• using opiates for pain management

• history of head injury, dementia, or mental retardation

• seizure disorder

• glaucoma

• unstable cardiac condition or arrhythmia

• moderate-severe pulmonary disease

• pregnancy